Výpis publikací

STYLIANOU, Filio; Adriana LADUNGOVÁ; Jan HÝL; Daniel BUŠA; Martin ČULEN; Barbora WEINBERGEROVÁ; Jiří MAYER a Michal ŠMÍDA. ANALYSIS OF ALTERNATIVE THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA PATIENTS RESISTANT TO VENETOCLAX BASED ON DRUG SCREENING AND EXPRESSION PROFILING. In III. ČESKÝ HEMATOLOGICKÝ A TRANSFUZIOLOGICKÝ SJEZD in Transfuze a Hematologie Dnes. 2024.

LADUNGOVÁ, Adriana; Filio STYLIANOU; Helena PESCHELOVÁ; Yusuf LODHI; Lenka DOSTÁLOVÁ; Narendra Varma GOTTUMUKKALA a Michal ŠMÍDA. EXPLORING VENETOCLAX RESISTANCE MECHANISMS IN AML CELLS THROUGH GENOME-WIDE CRISPR SCREENS AND DRUG PROFILING. In III. ČESKÝ HEMATOLOGICKÝ A TRANSFUZIOLOGICKÝ SJEZD in Transfuze a Hematologie Dnes. 2024.

JANOVSKÁ, Pavlína; Tomasz Witold RADASZKIEWICZ; P PROCHAZKOVA; Ingrid PRIŠTICOVÁ; Hana PLEŠINGEROVÁ; Martin ČULEN; Michal ŠMÍDA; Daniel BUŠA; Adriana LADUNGOVÁ; Lukáš MAIER; Štěpán HAVEL; Jiří MAYER; A SCHEER; Kamil PARUCH a Vítězslav BRYJA. Novel casein kinase 1 alpha inhibitors for the treatment of resistant AML and solid tumors. In 36th European-Organisation-for-Research-and-Treatment-of-Cancer / National-Cancer-Institute / American-Association-for-Cancer-Research Symposium on Molecular Targets and Cancer Therapeutics (EORTC/NCI/AACR). 2024. Dostupné z: https://doi.org/10.1016/j.ejca.2024.114893.

PESCHELOVÁ, Helena; Veronika MANČÍKOVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Dominika ŠKRNOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chornic lymphocytic leukemia. In CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko. 2023.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Dominika ŠKRNOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia. In PhD and PostDoc RETREAT, Sněžné, Milovy. 2023.

LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA; Jiří MAYER a Michal ŠMÍDA. Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening. In The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood. 2023.

GOTTUMUKKALA, Narendra Varma; Aneta LEDEREROVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Yusuf LODHI a Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity py preventing CD19 antigen escape in relapsed models. In EHA Meeting – 5th European CAR T-cell Meeting, Rotterdam, Nizozemsko. 2023.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In 23. Pražské hematologické dny, Praha. 2023.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. . Drug repurposing for venetoclax-resistant acute myeloid leukemia. In PhD retreat 2022, Telč. 2022.

DOSTÁLOVÁ, Lenka; Adriana LADUNGOVÁ; Dominika ŠKRNOVÁ; Narendra Varma GOTTUMUKKALA; Yusuf LODHI a Michal ŠMÍDA. Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells. In EHA 2022 in HemaSphere 2022; 6(S3): 1012-1013. 2022.

LODHI, Yusuf; Adriana LADUNGOVÁ; Daniel BUŠA; Helena PESCHELOVÁ; Martin ČULEN a Michal ŠMÍDA. Genome-wide Screening Optimizations and High-throughput Compound Screening to Identify Novel Treatment Options in Venetoclax-resistant AML. In Annual PhD conference Biomedical sciences, Brno. 2022.

GOTTUMUKKALA, Narendra Varma; Veronika MANČÍKOVÁ; Aneta LEDEREROVÁ; Veronika KOZLOVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Yusuf LODHI; Jan VERNER a Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. In XVII. Myeloma and Cell Therapy Workshop, Ostrava. 2022.

GOTTUMUKKALA, Narendra Varma; Veronika MANČÍKOVÁ; Aneta LEDEREROVÁ; Veronika KOZLOVÁ; Lenka DOSTÁLOVÁ; Adriana LADUNGOVÁ; Yusuf LODHI; Jan VERNER a Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. In Annual PhD conference Biomedical sciences, Brno. 2022.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In EHA 2022 in HemaSphere 2022; 6(S3): 626-627. 2022.

LADUNGOVÁ, Adriana; Daniel BUŠA; Helena PESCHELOVÁ; Yusuf LODHI; Martin ČULEN a Michal ŠMÍDA. Prediction of novel treatment options for CLL and AML cells based on drug repurposing. In CEITEC PhD Conference, Brno. 2022.

LADUNGOVÁ, Adriana; Daniel BUŠA; Yusuf LODHI; Jan HÝL; Martin ČULEN a Michal ŠMÍDA. Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing. In Functional Precision Medicine for Blood Cancer Workshop and Symposium, Helsinki, Finland. 2022.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Adriana LADUNGOVÁ; Veronika MANČÍKOVÁ a Michal ŠMÍDA. CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy. In XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 2021.

LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Veronika KOZLOVÁ a Michal ŠMÍDA. Drug repositioning in genetically defined CLL cases reveals a potentional novel therapeutic use for approved drugs. In II. Český hematologický a transfuziologický sjezd v Transfuze a Hematologie Dnes (2021). 2021.

LEDEREROVÁ, Aneta; Lenka DOSTÁLOVÁ; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Adriana LADUNGOVÁ; Martin ČULEN; Tomáš LOJA; Jan VERNER; Šárka POSPÍŠILOVÁ; Michal ŠMÍDA a Veronika MANČÍKOVÁ. Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro. Journal for ImmunoTherapy of Cancer. Switzerland: Springer International Publishing AG, 2021, roč. 9, č. 8, s. 1-8. ISSN 2051-1426. Dostupné z: https://doi.org/10.1136/jitc-2021-002352.

DOSTÁLOVÁ, Lenka; Aneta LEDEREROVÁ; Veronika KOZLOVÁ; Helena PESCHELOVÁ; Adriana LADUNGOVÁ; Tomáš LOJA; Jan VERNER; Šárka POSPÍŠILOVÁ; Veronika MANČÍKOVÁ a Michal ŠMÍDA. In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation. In II. Český hematologický a transfuziologický sjezd v Transfuze a Hematologie Dnes (2021). 2021.

KOZLOVÁ, Veronika; Aneta LEDEREROVÁ; Adriana LADUNGOVÁ; Helena PESCHELOVÁ; Pavlína JANOVSKÁ; A. SLUSARCZYK; J. DOMAGALA; Pavel KOPČIL; Viera VAKULOVÁ; Jan OPPELT; Vítězslav BRYJA; Michael DOUBEK; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. Plos one. San Francisco: Public Library Science, 2020, roč. 15, č. 3, s. 0229170-229189. ISSN 1932-6203. Dostupné z: https://doi.org/10.1371/journal.pone.0229170.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Adriana LADUNGOVÁ; Václav HEJRET a Michal ŠMÍDA. CRISPR/CAS9 technology: a useful tool in the study of chronic lymphocytic leukemia. In XXth Interdisciplinary meeting of young researchs and students in the field of chemistry, biochemistry, molecular biology and biomaterials in Chemické listy. 2020. ISSN 2336-7202.

MANČÍKOVÁ, Veronika; Helena PESCHELOVÁ; Veronika KOZLOVÁ; Aneta LEDEREROVÁ; Adriana LADUNGOVÁ; Jan VERNER; Tomáš LOJA; František FOLBER; Jiří MAYER; Šárka POSPÍŠILOVÁ a Michal ŠMÍDA. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. Journal for ImmunoTherapy of Cancer. Switzerland: Springer International Publishing AG, 2020, roč. 8, č. 1, s. 000471-481. ISSN 2051-1426. Dostupné z: https://doi.org/10.1136/jitc-2019-000471.

PESCHELOVÁ, Helena; Veronika KOZLOVÁ; Veronika MANČÍKOVÁ; Adriana LADUNGOVÁ; Václav HEJRET a Michal ŠMÍDA. The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. In CEITEC PhD Conference. 2020.

LADUNGOVÁ, Adriana. Tour through the drug screening in the lab of Functional Genomics. In Joint retreat 2019, Kouty u Ledče nad Sázavou. 2019. ISBN 978-80-210-9300-3.